Press Releases - G1 Therapeutics, Inc.

Press Releases

Date	Title
12/5/23	G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
12/1/23	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/29/23	G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
11/1/23	G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
10/27/23	Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
10/18/23	G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
10/18/23	G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023
10/16/23	G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
9/5/23	G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
9/1/23	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)